Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cardiovascular

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1534092

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1534092

Cardiomyopathy Therapies

PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5450
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16350

Add to Cart

Description

Table of Contents

Global Cardiomyopathy Therapies Market to Reach US$3.4 Billion by 2030

The global market for Cardiomyopathy Therapies estimated at US$3.0 Billion in the year 2023, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 1.7% over the analysis period 2023-2030. Dilated Cardiomyopathy, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Hypertrophic Cardiomyopathy segment is estimated at 1.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$822.0 Million While China is Forecast to Grow at 3.0% CAGR

The Cardiomyopathy Therapies market in the U.S. is estimated at US$822.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$625.0 Million by the year 2030 trailing a CAGR of 3.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Cardiomyopathy Therapies Market - Key Trends and Drivers Summarized

Cardiomyopathy is a complex and heterogeneous group of heart muscle diseases that impair the heart's ability to pump blood effectively. These conditions can be classified into several types, including dilated, hypertrophic, restrictive, and arrhythmogenic right ventricular cardiomyopathy. Each type has distinct etiologies, pathophysiologies, and clinical presentations, necessitating tailored therapeutic approaches. Current treatment options for cardiomyopathy range from pharmacological interventions such as beta-blockers, ACE inhibitors, and anticoagulants, to non-pharmacological strategies, including lifestyle modifications and the use of implantable devices like pacemakers and defibrillators. In severe cases, patients may require advanced therapies such as cardiac resynchronization therapy, ventricular assist devices, or even heart transplantation. Despite the variety of treatments available, managing cardiomyopathy remains challenging due to its progressive nature and the potential for sudden cardiac death.

Recent advancements in the understanding of molecular and genetic underpinnings of cardiomyopathy have paved the way for innovative therapeutic approaches. Gene therapy and molecular-targeted therapies are at the forefront of research, offering potential curative solutions for certain genetic forms of cardiomyopathy. For instance, CRISPR-Cas9 gene editing and RNA interference are being explored to correct or silence defective genes responsible for cardiomyopathy. Additionally, the development of novel pharmacological agents, such as myosin inhibitors and selective cardiac myosin activators, is aimed at directly modulating cardiac contractility and improving heart function. Stem cell therapy also holds promise, with ongoing clinical trials investigating its potential to regenerate damaged heart tissue and restore myocardial function. These cutting-edge therapies are complemented by advancements in diagnostic tools, including next-generation sequencing and advanced imaging techniques, which facilitate early and precise diagnosis, thereby enabling timely and targeted interventions.

The growth in the cardiomyopathy therapies market is driven by several factors. The rising prevalence of cardiovascular diseases, particularly in aging populations, has significantly increased the demand for effective cardiomyopathy treatments. Technological advancements in diagnostic and therapeutic modalities have expanded the range of available treatment options, making it possible to offer more personalized and effective care. Increased awareness and understanding of cardiomyopathy among patients and healthcare providers have led to earlier diagnosis and intervention, improving patient outcomes. Furthermore, substantial investments in research and development by pharmaceutical companies and academic institutions are accelerating the discovery and commercialization of novel therapies. Supportive government policies and favorable reimbursement frameworks in many regions are also playing a crucial role in making advanced treatments accessible to a broader patient population. Additionally, the integration of digital health technologies, such as remote monitoring and telemedicine, is enhancing patient management and adherence to therapy, thereby driving market growth. Collectively, these factors are fostering a dynamic and rapidly evolving market for cardiomyopathy therapies.

Select Competitors (Total 86 Featured) -

  • Abbott Cardiovascular
  • Alexion Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bio-Rad Laboratories, Inc.
  • Bristol Myers Squibb company
  • Cardiol Therapeutics, Inc.
  • Cipla Ltd
  • Cytokinetics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Diagnostics (Schweiz) AG
  • Tenaya Therapeutics;
Show more
Product Code: MCP26852

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Cardiomyopathy Therapies - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Cardiovascular Diseases Spurs Demand for Cardiomyopathy Therapies
    • Technological Advancements in Diagnostic Modalities Propel Growth
    • Gene Therapy and Molecular-Targeted Treatments Expand Addressable Market Opportunity
    • Increased Awareness and Early Diagnosis Strengthen Business Case for Innovative Therapies
    • Development of Novel Pharmacological Agents Generates New Market Opportunities
    • Here's How Advancements in Stem Cell Therapy Drive Market Dynamics
    • Growing Focus on Personalized Medicine Drives Adoption of Tailored Treatment Approaches
    • Integration of Digital Health Technologies Sustains Growth in Patient Management
    • Expansion of Telemedicine Services Enhances Access to Cardiomyopathy Care
    • Rising Geriatric Population Throws the Spotlight On Need for Comprehensive Cardiac Care
    • Here's the Story: Impact of Advanced Imaging Techniques on Early and Accurate Diagnosis
    • Evolution of Multimodal Treatment Strategies Drives Comprehensive Patient Care
    • Advances in Biomarker Discovery Generate Opportunities for Precision Medicine
    • Trend towards Outpatient Cardiac Care Spurs Demand for Non-Invasive Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cardiomyopathy Therapies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cardiomyopathy Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Dilated Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Dilated Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Dilated Cardiomyopathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hypertrophic Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hypertrophic Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Hypertrophic Cardiomyopathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • CHINA
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Cardiomyopathy Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Cardiomyopathy Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • INDIA
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Cardiomyopathy Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Cardiomyopathy Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!